Clinical Trials Logo
  1. Home
  2. Parkinson's Disease (PD)
  3. NCT02017938
  4. Details
NCT02017938 Clinical Trial

Establishing the Central and Peripheral Fatigue Indexes and VR Based Anti-fatigue Training Paradigm for Individuals With Parkinson Disease

Parkinson's Disease (PD) Clinical Trial

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT02017938
Other study ID # 101-5141B
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 10, 2014
Est. completion date July 31, 2016

Study information
Verified date March 2024
Source Chang Gung University
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Fatigue is one of the most common symptoms in individuals with Parkinson's Disease (PD). Past researches indicated that more than half of the individuals with PD demonstrated fatigue symptom. The severity of fatigue was also correlated to the quality of life in individuals with PD. Finding the contributions of the central and the peripheral factors to fatigue, building reliable fatigue indexes, and developing an effective training program for individuals with PD are very important. The purpose of this project is to develop non-invasive method to monitor central and peripheral fatigue, to establish Virtual Reality(VR) anti-fatigue ergo cycling training paradigm, and to evaluate the long term training effect in individuals with PD.

Recruitment information / eligibility
Status Completed
Enrollment 31
Est. completion date July 31, 2016
Est. primary completion date July 30, 2015
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 20 Years and older
Eligibility Inclusion Criteria: - Clinical diagnosis of Parkinson disease - Hoehn and Yahr ?3 Exclusion Criteria: - Musculoskeletal injuries - Osteoporosis - Diabetes - Any peripheral or central nervous system injury or disease patients

Study Design

Related Conditions & MeSH terms

Intervention

Procedure:
• Virtual Reality anti-fatigue ergo cycling training (Self-made)
To establish a Virtual Reality systems to reduce fatigue of cycling training for PD subjects.

Locations
Country Name City State
Taiwan Chang Gung University Taoyuan

Sponsors (1)
Lead Sponsor Collaborator
Chang Gung University

Country where clinical trial is conducted

Taiwan, 

Outcome
Type Measure Description Time frame Safety issue
Primary Muscle twitch force Measure of changes in muscle twitch force by interpolation twitch technique. baseline, 1 week
Primary Muscle voluntary activity level Measure of changes in muscle voluntary activity level by interpolation twitch technique. Baseline,1 week
Primary Heart rate/Heart rate variability Measure of changes in Heart rate/Heart rate variability. Baseline,1 week
Primary Borg's rate of perceived exertion Measure of changes in Borg's rate of perceived exertion. Baseline,1 week
See also
  Status Clinical Trial Phase
Completed NCT02170376 - The Effect of BIA 9-1067 at Steady-state on the Levodopa Pharmacokinetics Phase 1
Completed NCT02169895 - Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Immediate-release Levodopa/Benserazide Phase 1
Completed NCT02169479 - Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Diferente Single Doses of BIA 9-1067 and a Single-dose of Immediate-release 100/25 mg Levodopa/Carbidopa Phase 1
Completed NCT02778594 - Pharmacokinetic-pharmacodynamic Interaction Between BIA 3-202 and Levodopa/Benserazide Phase 1
Completed NCT02274766 - Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia Phase 3
Completed NCT02169453 - Pharmacokinetic-pharmacodynamic Interaction Between Each of Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Carbidopa Phase 1
Completed NCT04380142 - Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease Phase 3
Withdrawn NCT06118294 - Efficacy of Probiotics for Parkinson Disease (PD) N/A
Recruiting NCT05916157 - An Observational Study of Subcutaneous Infusion of ABBV-951 to Assess Change in Disease Activity and Adverse Events In Adult Japanese Participants With Advanced Parkinson's Disease
Completed NCT03033498 - A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Subcutaneous Infusions of ABBV-951 in Subjects With Parkinson's Disease Phase 1
Completed NCT02169427 - An Open-label Study in Healthy Male Subjects to Assess the Absorption, Distribution, Metabolism and Excretion of [14C]-Labelled BIA 9-1067 and Metabolites Phase 1
Completed NCT02834507 - Effect of Two Multiple-dose Regimens of BIA 3-202 on the Pharmacokinetics and Motor Response of Levodopa, and on the Erythrocyte Comt Activity in Parkinson's Disease Patients Phase 2
Active, not recruiting NCT04379050 - Extension Study To Evaluate Safety And Tolerability Of 24-Hour Daily Exposure Of Continuous Subcutaneous Infusion of ABBV-951 In Adult Participants With Parkinson's Disease Phase 3
Completed NCT02169440 - Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin Phase 1
Completed NCT02202551 - Open-Label Safety Study of ADS-5102 in PD Patients With LID Phase 3
Completed NCT01398748 - Intranasal Glutathione in Parkinson's Disease Phase 1
Recruiting NCT06107426 - Real-World Study of ABBV-951 Subcutaneous Infusion to Assess Change in Disease Activity in Adult Participants With Parkinson's Disease
Completed NCT02169466 - Pharmacokinetic-pharmacodynamic Interaction Between Three Different Single Doses of BIA 9-1067 and a Single-dose of Controlled-release 100/25 mg Levodopa/Benserazide Phase 1
Recruiting NCT03732898 - Coordinated Reset Deep Brain Stimulation N/A
Completed NCT02799381 - A Study Comparing Efficacy of Levodopa-Carbidopa Intestinal Gel/Carbidopa-Levodopa Enteral Suspension and Optimized Medical Treatment on Dyskinesia in Subjects With Advanced Parkinson's Disease (DYSCOVER) Phase 3